Comparing the current results to its competitors, Celcuity Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 2.47 %, recorded in the same quarter.
August 27, 2025
In a significant development for cancer treatment, Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focusing on the development of targeted therapies for oncology, announced its plan to initiate a New Drug Application (NDA) submission for its investigational drug, gedatolisib. This submission is for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) and will occur under the U.S. Food and Drug Administration s (FDA) Real-Time Oncology Review (RTOR) program. The initiative allows for a streamlined process that enables the agency to evaluate key efficacy and safety data earlier than traditional applications.T...
February 22, 2024
Celcuity Inc., a clinical-stage biotechnology company, has initiated a Phase 1b/2 clinical trial (CELC-G-201) to evaluate the effectiveness of gedatolisib in combination with Nubeqa for the treatment of metastatic castration resistant prostate cancer (mCRPC). Gedatolisib, Celcuity s leading therapeutic candidate, is a powerful dual inhibitor that selectively targets all Class 1 PI3K isoforms and mTORC1/2. This article aims to outline the key facts regarding the initiation of this clinical trial.Clinical Trial Details:The Phase 1b/2 clinical trial, CELC-G-201, conducted by Celcuity, has commenced with the administration of gedatolisib to its first patient. This trial aims to investigate the potential of gedat...
Aprea Therapeutics Inc is a biopharmaceutical company with a business model focused on developing and commercializing innovative cancer therapies. They aim to leverage their proprietary discovery platform to identify and develop small molecules that selectively target and restore the tumor suppressor protein p53. Their business strategy includes conducting clinical trials, seeking regulatory approvals, and partnering with other organizations for commercialization and distribution.
Catalyst Pharmaceuticals Inc operates under a business model where it develops and commercializes novel drugs to address unmet medical needs primarily in the field of rare diseases. The company focuses on conducting clinical research, obtaining necessary regulatory approvals, and marketing its products to healthcare professionals and patients. Catalyst Pharmaceuticals Inc aims to generate revenue through the sale of its approved drugs and by seeking partnerships or collaborations for the development and commercialization of new products.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Sources:
Celcuity Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Celcuity Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
